Aethlon Medical (NASDAQ:AEMD) Stock Lifted to “Sell” by Wall Street Zen

Wall Street Zen upgraded shares of Aethlon Medical (NASDAQ:AEMD) to a sell rating in a research note released on Saturday,Wall Street Zen reports.

AEMD has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aethlon Medical in a report on Thursday. HC Wainwright reaffirmed a “neutral” rating on shares of Aethlon Medical in a research note on Friday, September 18th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $1.50.

Aethlon Medical Stock Performance

Shares of NASDAQ AEMD opened at $5.15 on Friday. Aethlon Medical has a 1 year low of $1.41 and a 1 year high of $29.45. The stock’s 50-day simple moving average is $3.98 and its 200-day simple moving average is $6.73. The firm has a market cap of $3.66 million, a price-to-earnings ratio of -0.15 and a beta of 1.21.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings data on Thursday, August 13th. The medical equipment provider reported ($4.02) EPS for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10). As a group, research analysts predict that Aethlon Medical will post -5.74 EPS for the current year.

Aethlon Medical Company Profile

Aethlon Medical, Inc is a medical technology company focused on developing extracorporeal filtration systems designed to remove harmful biological materials from the blood. The company’s primary technology is the Hemopurifier, an investigational device intended to capture disease-related particles, including exosomes and certain viruses, during blood filtration.

The Hemopurifier is being studied for potential applications in oncology and infectious disease. In cancer research, the device is designed to remove tumor-derived exosomes, which may contribute to immune suppression and disease progression.